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Background: The development of resistance by P. falciparum to most drugs used in prophylaxis and therapeutics 
underscores the need to investigate the sensitivity of local parasite isolates to the currently available standard antimalarial 
drugs. 
Objective: To assess parasitological resistance and therapeutic efficacy of mefloquine (MQ) and 
sulfadoxine/pyrimethamine (SP) in children with uncomplicated falciparum malaria in Metehara town, southeast 
Ethiopia. 
Methods: The therapeutic responses to MQ and SP were examined using the World Health Organization 14-day in 
vivo test protocol. A total of 119 children that fulfilled the inclusion criteria were assigned to the MQ (n=59) or SP 
(n=50) treatment group. The patients were followed up for 14 days, and clinical and parasitological outcomes were 
assessed. 
Results: The 14-day clinical and parasitological cure rates in children treated with MQ were found to be 100% (55/ 
55) with no recrudescence until day 14. In the SP group, the clinical cure and failure rates were found to be 78.9 % 
(45/57) and 12% (7/57) respectively. Out of the patients with clinical failure in the SP group, one child was classified 
as early treatment failure and six had late treatment failure. The incidence of parasitological resistance was 21.1 % (8 
patients with RI and, 4 patients with RII). MQ was faster in fever and parasite clearance rate by day 2 (76.4%) and day 
3 (98.2%) than in the SP group (64.9% day 2 and 91.2% day 3).  Gametocyte carrier rate following therapy was 
significantly lower in those treated with MQ than in those receiving SP; 1.8% with MQ had gametocytes by day 14 
compared to 50.9 % with SP (P= < 0.001). Adverse events to both drugs were mild and a few with no incidence of 
characteristics of MQ and SP induced psychosis or Steven Johnson, respectively. 
Conclusion: These findings show that MQ (15mg base/kg), administered as a single oral dose, was highly effective 
and well tolerated in the treatment of uncomplicated falciparum malaria achieving a cure rate of 100% of treated 
children in this endemic area. However, a dramatic increase in the frequency of parasite resistance to SP was 
demonstrated compared with the incidence two years previously.  [Ethiop.J.Health Dev. 2005;19(3)167-173] 
 
Introduction 
Appropriate treatment with effective antimalarial drugs is 
accepted as a principal strategy for malaria control 
worldwide (1). The increasing resistance of Plasmodium 
falciparum to chloroquine (CQ), the mainstay of 
antimalarial therapy for the past 50 years, has made the 
choice of antimalarial therapy for prevention and treatment 
of this infection much more difficult in Africa (2). 
Widespread P. falciparum persistance to CQ has been 
associated with increased childhood mortality and 
morbidity in Africa (3). This situation has led to an 
increased use of drugs like halofantrine, which are more 
expensive and may be even toxic (4). 
 
Sulfadoxine/pyrimethamine (SP) is usually considered the 
cheapest alternative to CQ for the treatment of 
uncomplicated falciparum malaria in large parts of Africa. 
Consequently, SP has replaced CQ as a first line therapy for 
uncomplicated falciparum in several African countries 
including, Malawi, Tanzania, Kenya and Botswana (2). 
However, clinical resistance to SP has developed rapidly in 
Tanzania (5) and Kenya (6) where SP has already replaced 
CQ as a first line drug. Besides, strains of in vivo resistant 
P. falciparum have been reported in virtually all 
antimalarial drugs except artimisinin and its derivatives (7). 
Thus, such spread of resistance of P. falciparum to almost 
all drugs used in prophylaxis and therapeutics emphasizes 
the need for more information on the sensitivity of local 
parasite isolates to the available antimalarial drugs. Such 
information should lead national malaria control programs 
to adopt their therapeutic schedules to changes in P. 
falciparum susceptibility.  
 
In Ethiopia, increasing CQ resistance has led to a national 
antimalarial policy change in 1999 from CQ to adopting 
SP as a first line drug for the treatment of uncomplicated 
falciparum malaria (8, 9). However, CQ still remains first 
line for P. vivax and P. malarae, with quinine being 
second line and reserved for severe malaria. An initial 
national survey undertaken between 1996 and 1998 by 
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the MOH demonstrated less than 10% treatment failure 
for SP (7, 8). Since then, mean total treatment failure 
rates of 22- 72% were reported from sentinel sites in 
2003 (10). 
 
In Ethiopia, malaria patients infected with parasites that 
are resistant to SP or CQ are often treated with quinines, 
(9). However, quinines are largely unavailable at the 
lower level health facilities that operate around endemic 
areas. In view of the prevailing CQ resistant strains of P. 
falciparum, CQ of 300mg (as base, two tablets) weekly 
plus proguanil 200mg (two tablets) daily is currently 
recommended as a prophylaxis in the country (9). 
However, compliance with this regimen may be poor, 
due to the daily administration of proguanil. Mefloquine 
(MQ) is now widely recommended for antimalarial 
chemoprophylaxis worldwide (11,12) and has been shown 
to be highly effective in the treatment of CQ and SP- 
resistant P. falciparum in African children (13,14) and 
pregnant women (15).  
 
MQ has not yet been officially used for malaria control in 
Ethiopia. However, travellers coming to the country often 
take MQ as a prophylaxis. Currently, the Ministry of Health 
is also considering to introduce MQ for prophylaxis in the 
country (10). Despite its wide prophylactic use, MQ 
prophylaxis and treatment failure have been reported in 
some African countries even before the drug was widely 
used (16, 17). However, the authors of this study have not 
seen any published report of either in vivo or in vitro 
response of local malaria parasite isolates to MQ. 
 
In the event that MQ is to be added in the list of drugs for 
the treatment or prophylaxis of malaria in this country in 
the near future, a study was undertaken in 2002 that 
examined the in vivo sensitivity of P. falciparum 
parasites to MQ and SP in Metehara town. Comparison 
of the present SP sensitivity of P. falciparum was also 
made with results from previous studies conducted by the 
same team on the same site (18). 
 
Methods 
Study area and population 
The study was carried out between October and 
November, 2002 during the peak transmission season at 
the outpatient department of Metehara Sugar Estate 
Hospital. Metehara is situated in the Rift Valley area, 
about 210 kms east of Addis Ababa.  The Estate 
irrigation system depends on the nearby Awash River for 
the cultivation of sugar-cane. The irrigation development, 
in turn, provides breeding sites for the Anopheles 
mosquito. Malaria transmission in this area occurs 
perennially with peaks during the two rainy seasons 
(September – November and March - May). This area is 
endemic for both P. falciparum and P. vivax, P. 
falciparum accounting for 80% of malarial infections 
while the remaining 20% is caused by P. vivax (Metehara 
Sugar Estate Hospital health records, unpublished data). 
A previous trial at this study site demonstrated an 8% 
incidence of P. falciparum resistance to SP (18). 
 
The study was based on the standard 14-day in vivo 
WHO protocol (19) except that the study population 
consisted of children aged one to seven years old who 
were attending the outpatient department with symptoms 
of malaria. WHO stresses the preferential inclusion of 
young children aged < 5 years in all treatment efficacy 
studies even if all ages could be enrolled in areas of low 
transmission. The inclusion of children aged one to seven 
years old in this study was mainly due to the prevailing 
difficulty of attaining the target sample size. 
 
The children were selected for the study according to the 
following criteria: axillary temperature of  ≥ 37.5 and < 
39.5 
0
C at the time of visit or a recent history of fever; a 
body weight of > 5 kg; P. falciparum mono-infection, 
with asexual parasitemia ranging between 1000 to 
140,000/µl.; no antimalarial drug administration in the 
preceding two weeks before presentation; residing in the 
trial center or the surrounding village within a 15 km 
radius; haemoglobin of > 5.0 gm/dL. Patients were 
recruited based on written informed consent obtained 
from patients'  parents/guardians. 
 
A child was excluded from the study if danger signs or 
concomitant febrile illnesses that interfere with outcome 
classification emerged during the follow-up period. 
Ethical clearance was obtained from the Research and 
Ethical Committee of the Ethiopian Health and Nutrition 
Research Institute. 
 
Treatment and follow-up 
A total of 762 children with symptoms suggestive of 
malaria were screened between October and November 
2002. Overall 119(16%) consecutive children aged 1- 7 
years of age and who met the inclusion criteria were 
readily assigned to receive either MQ (n=59) (mephaquin 
mepha Ltd, Aesch-Basel, Switzerland, 15 base/kg) or SP 
(n=60) (MALAREICH, Smithkline Beechman, 
sulfadoxine 25mg/kg + pyrimethamine 1.25 mg/kg) 
tablets on D0 (19). Tablets were given intact to older 
children or crushed in the form of syrup to young 
children. The dosage was adjusted according to the 
patient’s body weight (7). Children with an axillary 
temperature of 38.5
0
 C or higher were given a single dose 
of paracetamol tablet at 15mg/kg and were treated with 
tepid sponging and fanning when necessary before 
administering the antimalarial drug. All children were 
given the medication orally under supervision and were 
monitored for 30 min. If the children vomited the first 
dose, a second full dose was administered. Children 
vomiting more than once were withdrawn from the study 
immediately and admitted to the hospital for appropriate 
treatment. 
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Children were followed at days 2, 3, 7 and 14. Parents 
were asked to bring the children to the hospital any time 
the children were sick. If the children failed to appear at 
the scheduled days, they were visited at home. On each 
follow-up visit, clinical examinations, temperature 
measurement, blood smears, presence of any adverse 
reactions to the drugs were recorded. Hemoglobin was 
measured at the day of registration and at day 14 with a 
colorimetric method using Drabkin’s solution.  
 
Thick and thin blood films were stained with Giemsa 
stains.  All slides were read by a microscopist who did 
not have prior information as to the treatment groups and 
clinical outcomes. Parasite density was measured as the 
number of parasites per 200 leucocytes on a thick film, 
assuming total leucocytes of 8000/µL. Blood films were 
considered negative if no asexual forms of P. falciparum 
were observed with 200 high power fields. Gametocytes 
were counted in thick blood smears against 1000 
leukocytes and species confirmed on thin blood smears. 
 
All treatment failures and dropout cases were treated in 




Outcomes were evaluated primarily by clinical and 
parasitological responses to therapy over 14 days (19). 
Clinical responses were defined as early treatment failure 
(ETF), if the patients developed signs of danger or severe 
malaria on or before day three, had fever and if axillary 
temperature was ≥ 37.5 
0
C on day two with parasitemia 
greater than the day zero count, or if axillary temperature 
was ≥ 37.5 
0
C on day three in the presence of 
parasitemia, or if parasitemia on day three was ≥ 25% of 
the count on day zero. Late treatment failure (LTF) 
means that parasitemia on day three was less than 25% of 
day zero count and development of signs of danger or 
severe malaria developed on any day from day four to 
day fourteen in the presence of parasitemia, or if 
parasitemia on day three was less than 25% of the count 
on day zero and axillary temperature was ≥ 37.5 
0
C in the 
presence of parasitemia on any day from day four to day 
fourteen. All others were classified as adequate clinical 
response (ACR) cases. ACR means that parasitemia on 
day three was less than 25% of count on day zero and no 
parasitemia on day fourteen; or parasitemia on day three 
was less than 25% of the count on day zero even if 
parasites were present on day fourteen, and axillary 
temperature is below 37.5 
0
C. Parasitological response 
was classified as S, RI, RII, RIII responses where, S 
indicates no parasite detectable on day fourteen; RI: day 
three parasite density <25% of day zero density, no 
parasite detectable on day seven, and reappearance on 
day fourteen; RII: parasite density on day three < 25% of 
day zero density and parasites detectable on day seven 
and day fourteen; RIII: parasite detectable on day three 
and day seven (parasite count on day three ≥25% of 
initial parasite count on day zero). Secondary endpoints 
included fever and parasite clearance rates, presence of 
gametocytes on days, 3, 7, and 14, change in hemoglobin 
mean value from day zero to day fourteen and occurrence 
of adverse events. Adverse drug reaction is defined as the 
development of any symptom or sign that does not exist 
before the initiation of treatment and that is not a classic 
symptom of malaria. 
 
Sample size: The sample size was calculated with an 
estimated 0.25 upper and 0.10 lower levels of treatment 
failure and with 80% power at a 5% significant level 
(19). Taking into account a dropout rate of 10%, 60 
patients per treatment group were enquired. 
 
Statistical analysis 
Data was fed into the SPSS computer software. A 
comparison was made between the two treatment groups 
using chi-square (for proportion) and t-tests (for normally 
distributed continuous data). Non-parametric tests, 
especially the Man-Whitney U test, were employed as 
deemed appropriate.  
 
Results 
Out of 119 (16%) children enrolled in the study, four 
children in the MQ group and three children in the SP 
group did not complete the 14 days follow up and were 
excluded from the study. The reasons for withdrawal 
included repeated vomiting following therapy (3 MQ, 1 
SP), not available for follow ups (one in each group) and 
convulsion following therapy and were immediately 
admitted to the hospital. None of the enrolled children 
died. The overall dropout rate was 6 % (7/119). Thus, 
112 patients (55 MQ, 57 SP) have successfully 
completed the study and their data were evaluated.  
 
The baseline demographic, clinical and laboratory data 
were compared between the two treatment groups (Table 
1). There was, however, no significant difference 
between MQ and SP regimens with respect to the 
distribution of baseline attributes. 
 
The14-day clinical and parasitological responses to 
therapy are shown in Tables 2. MQ was significantly 
more efficacious than SP in either clinical or 
parasitological responses. The clinical cure rate (ACR) 
for MQ was 100% compared with 87.7% for SP. There 
was no clinical or parasitological failure in the MQ 
group. In the SP group, the combined frequency of ETF 
and LTF was 21% (one child was classified as ETF and 
six-exhibited LTF). 
 
Using the parasitological classification 21.1 % (12/55) of 
the children in the SP group experienced RI/RII (8 RI, 4 
RII) responses and 78.9% (45/47) showed the S response. 
One patient who was classified as ETF on day three in 
the SP group had a parasite density lower than 25% of 
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Table 1: Baseline characteristics of children who have completed the study and who were  
enrolled with uncomplicated Plasmodium falciparum and treated with mefloquine 
or sulfadoxine/pyrimethamine, Metehara, Ethiopia, Oct-Nov. 2002 
                        Treatment group 







 (years) 3.98 (1.48)  3.75 (1.56) 0.432 
<5 years (%) 38 (69.1) 43 (75.4) 0.528 
Female(%) 27 (49.1) 26 (45.6) 0.850 
Weight
a





C) 38.5 (0.92) 38.4 (0.82) 0.242 
No. ≥37.5 54 (98.2) 50 (87.7) 0.726 
Parasitaemia
b
 (per µL) 






0.528    
Hemoglobine g/dL
a
 7.7 (2.0) 7.8 (2.0) 0.448 
 a
Mean (SD)  
 b
Geometric mean (range) 
 
The therapeutic responses of the infections to the drug 
treatments are summarized on Table 3. The rate of fever 
clearance  was  significantly  higher in children receiving 
MQ than those in the SP group. By days two and three, 
87% and 96.3% of the children respectively in the MQ 
group were afebrile compared to 60% and 86% 
respectively, in the SP group. Most patients treated with 
MQ had their parasites cleared by day two (76.4%) and 
day three (98.2%) in the MQ group than in the SP group 
(64.9% day 2 and 91.2% day 3). Nevertheless, these 
differences were not statistically significant. The 
gametocyte rate at baseline was not significantly different 
between the two treatments (7.3 MQ vs. 12.3 SP, P=0.53) 
groups (Table 1). However, the proportions of patients 
with gametocyte on day 7(12.7% MQ vs. 66.1% SP, 
P=<0.001) and day14 (1.8% MQ vs. 50.9% SP, 
P=<0.001) were significantly lower in the MQ group 
than in the SP group (Table 3). 
 
The mean haemoglobin level increased in the MQ group 
from an initial value of 7.7g/dL (SD= 2.0) at baseline 
(Table 1) to 8.4 g/dL (SD= 2.0)) at day 14 (P=0.08) in 
children treated with MQ, but not in the SP group (7.8 vs. 
7.8 g/dL, P=0.88) (Table 3). Nevertheless, the difference 
in haematological responses between the two treatment 
groups was not statistically significant (P=0.11). 
 
Adverse reactions to both drugs were mild and were 
resolved without treatment. 
 
Table 2: Parasitological and clinical responses of children with uncomplicated falciparum malaria 
following treatment with mefloquine or sulfadoxine/pyrimethamine, Metehara, Ethiopia, Oct-Nov. 2002 






Parasitological Response at 
Day 14 (%)*
 
   
S 55 (100) 45 (78.9) < 0.001 
RI 0 8 (14)  
RII 0 4 (7)   
RIII 0 0  










ETF 0 1                      
LTF 0  6                     
ETF+LTF 0 7 (12.3)  
*S, sensitive; R resistant 
**ACR, adequate clinical response; ETF, early treatment failure; LTF, late treatment failure. 
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Table 3: Therapeutic responses to mefloquine or sulfadoxine/pyrimethamine of children with  
uncomplicated falciparum malaria, Metehara, Ethiopia, Oct- Nov. 2002 






# fever cleared (%)
++
  
     Day 2 47 (87.0) 30 (60.0) 0.003 
     Day 3 52 (96.3) 43 (86.0) 0.010 
# parasite cleared (%) 
     Day 2 42 (76.4) 37(64.9) 0.217 
     Day 3 54 (98.2) 52(91.2) 0.206 
# With gametocyte (%) 
Day 3 10 (18.2) 7 (12.3)  0.384 
Day 7 7 (12.7) 37 (66.1)  <0.001 
Day 14 1 (1.8) 28 (50.9)  <0.001 
Hemoglobin g/dL at Day14 (%)
a




 Fever cleared among patients febrile at enrollment 
 
On admission, 5.1% (3 of 59) of the children assigned to 
receive MQ vomited the medication twice compared with 
1.7% (1 of 60) of those in the SP group (p= 0.59) and 
were withdrawn from the study. Vomiting occurred after 
drug administration in 7% (4 of 55) of the patients treated 
with MQ and 5.3 %( 3 of 57) of those treated with SP 
(p=0.96) 
 
Diarrhoea was reported in 16.4% (9 of 55) and 17.5% (10 
of 57) receiving MQ and SP (p=0.93), respectively; 9.1% 
(5 of 55) of the children in the MQ and 15.8% (9 of 57) 
in the SP (p=0.43) experienced reduced feeding; 3.6% (2- 
of 55) children experienced abdominal pain in the MQ 
group and none in those given SP. Overall only one child 
experienced dizziness on days one and two following 
therapy with MQ, which was possibly considered to be 
related to treatment with MQ (Table 4).  
 
Table 4: Adverse reactions in children with uncomplicated falciparum malaria following treatment  










Diarrhea 9 (16.4) 10 (17.5) 0.93 
Reduced feeding 5 (9.1) 9 (15.8) 0.43 
Vomiting 4 (7) 3 (5.3) 0.96 
Abdominal pain 2 (3.6) 0 NA 
Dizziness 1 0 NA 
NA, not applicable 
 
Discussion 
The main finding of this trial was that MQ (15mg 
base/kg) given as a single oral dose was highly effective 
and well tolerated in the treatment of uncomplicated 
falciparum malaria in children in this endemic area. All 
children who received MQ treatment were cured with no 
recrudescence until day 14. These findings are consistent 
with results from previous studies that have shown a 
100% cure rate with MQ in Nigerian children (13). 
However, these data contrast with findings in Cameron 
(16) and Malawi (17), where high failure rate of MQ was 
observed even before it was being widely used. 
 
The result of this study also indicated a dramatic increase 
in the incidence of SP resistance in this area. SP 
resistance was 8% in 2000 (18) and this figure has risen 
to 21% in the present study. This represents a marked 
increase in resistance compared with the same area 2 
years earlier. In support of the results of this study a more 
recent national survey undertaken by the Ministry of 
Health has revealed a total treatment failure rate of about 
22 % for SP at Metehara (10).  Similarly, P. falciparum 
resistance to SP has reached severe levels in 
neighbouring East African countries that adopted SP as a 
first line drug (4, 5). 
 
Both drugs are not gametocidal (7).  However, in the 
present study treatment with SP was associated with a 
significantly higher level of gametocyte rate than 
treatment with MQ. More than 50% of patients treated 
172     Ethiop.J.Health Dev. 
______________________________________________________________________________________ 
 
Ethiop.J.Health Dev. 2005;19(3) 
with SP had gametocytes on day 14.These findings are 
consistent with results from previous studies in the same 
study area (18) and elsewhere (20), which showed a 
similar increased gametocyte rate following treatment 
with SP. Such increase in gametocyte carrier rate might 
escalate the transmission of P. falciparum and the spread 
of resistant parasites in the study area. 
 
Adverse events to both drugs were mild and few. 
Besides, no clinically relevant difference between the 
study groups was observed with respect to adverse drug 
effects. Mefloquine has been associated with psychosis 
(21) however, such psychiatric reaction has never been 
observed with the use of MQ (15 mg base/kg) at the dose 
used for the treatment of malaria in this area. Vomiting 
and nausea were the most common MQ related adverse 
reactions (7). These occurred in only four and one child 
treated with this drug respectively. Besides, we recorded 
no incidence of Steven Johnson under SP treatment, a 
well-known side effect of this drug (7) 
 
These findings show that MQ (15mg base/kg), 
administered as a single oral dose, was highly effective 
and well tolerated in the treatment of uncomplicated 
falciparum malaria, achieving a cure rate of 100% in 
treated children in Metehara. Given that MQ is effective 
against the blood forms of P. vivax malaria (7) it appears 
to be a valuable addition to the list of drugs for 
prophylaxis and the treatment of malaria in the country. 
Increasing SP resistance in P. falciparum in the study 
area is among the most important findings of this study. 
In view of the high level of SP resistance, the Ministry of 
Health is currently in the process of changing the first 
line drug from SP to Coartem a combination of 
artemether and lumefanthrine. However, the treatment is 
too expensive for wider use in resource poor countries 
such as Ethiopia. Although there is international support 
for Coartem at the moment, its sustainability in the long 
run is an area of concern. In addition, the diagnostic 
facilities should be strengthened to ensure the use of 
these valuable drugs only to laboratory confirmed cases. 
 
The main limitation of this study is that it stopped at 14 
days of follow up which might have been too early to 
judge the occurrence of recrudescence or late emergent 
parasites under MQ treatment. Previous studies have 
demonstrated that most failures with MQ occur after a 
month following therapy (22). These studies suggest 
follow-up periods up to 42 days to detect recrudescence 
parasites with MQ treatment. Therefore, the standard 14-
day follow up recommended by WHO (19) for areas of 
intense transmission, which is applied in the present 
study might not have been sufficient to detect the late 
emergence or resistance of parasites with MQ. In this 
context, our results may underestimate the true 
recrudescence rate. This however does not affect the 
study outcome very much given that the WHO standard 
test method is still not well suited to differentiate new 
infection from recrudescence if the length of follow up 
period is extended beyond 14 days (19). 
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